Shares of Nevro (NVRO) Sees Large Inflow of Net Money Flow

Nevro (NVRO) : Wednesdays money flow indicated an uptick to downtick ratio was at 1.37. The total value of inflow transactions on upticks was $11.11 million, whereas, the total value of outflow trades on downticks was $8.14 million. The total money flow was $2.97 million, which shows a mild bullish bias. The total money flow into the stock in block trades was $1.74 million. The total value of the trades done on upticks was $1.74 million. Nevro (NVRO) was trading with a -1.1% change over previous days close. It fell $1.15 during the day and reached $103.79. The stock was 1.75% compared to the previous weeks close.


Shares of Nevro Corp. rose by 5.74% in the last five trading days and 8.4% for the last 4 weeks. Nevro Corp. is up 45.1% in the last 3-month period. Year-to-Date the stock performance stands at 54.08%.

Nevro (NVRO) : Zacks Investment Research ranks Nevro (NVRO) as 3, which is a Hold recommendation. 7 research analysts consider that the stocks fundamentals point to a bright future, hence they rate the stock as a Strong Buy. 1 other analysts are mildly bullish on the stock and favor a Buy. A total of 1 analysts believe that the stock has a limited upside, hence they advise a Hold. The average broker rating of 9 research analysts is 1.28, which indicates as a Strong Buy.

Nevro (NYSE:NVRO): stock was range-bound between the intraday low of $103 and the intraday high of $105.225 after having opened at $104.58 on Wednesdays session. The stock finally closed in the red at $104.58, a loss of -0.88%. The stock remained in the red for the whole trading day. The total traded volume was 516,280 shares. The stock failed to cross $105.225 in Wednesdays trading. The stocks closing price on Thursday was $104.94.

Nevro Corp. is a medical device company. The Company manufactures and markets active implantable medical devices for the treatment of neurological disorders initially focusing on the treatment of chronic pain. The Company developed and commercialized a neuromodulation platform for the treatment of chronic pain. The Companys Senza system is the only spinal cord stimulation (SCS) system that delivers its HF10 therapy. The Companys Senza system creates electrical impulses from two hertz to 10 kilohertz, including its HF10 therapy, which allows for pain relief without paresthesia. HF10 therapy delivers waveforms at 10 kilohertz pulse rate with a statistically driven and clinically verified programming algorithm. Senza consists of leads, a trial stimulator, an implantable pulse generator (IPG), surgical tools, a clinician laptop programmer, a patient remote control and a mobile charger.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *